Clinical trials: Chronic Leukaemia
Leukaemia, Lymphocytic, Chronic
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01563055
- Testing
- chlorambucil, tablets, ofatumumab (GSK1841157) infusion
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in…
- Trial name
- NCT04210219
- Testing
- JNJ-64264681
- Where
- 15 sites in United States, Georgia and 5 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Myeloid Leukemia
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
- Trial name
- NCT00462943
- Testing
- Omacetaxine mepesuccinate
- Where
- 29 sites in United States, Canada and 8 more
- Volunteers
- 100 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Lymphocytic Leukemia, Leukemia
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Neoplasms
- Trial name
- CLL (NCT01657955)
- Testing
- Bendamustine Hydrochloride Injection, Chlorambucil
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Trial name
- NCT03647215
- Where
- 33 sites in Ireland, United Kingdom
- Volunteers
- 427 people
- Sponsor
- Incyte Biosciences UK
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
- Trial name
- NCT03853616
- Testing
- MB-CART19.1
- Where
- 9 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Miltenyi Biomedicine GmbH
CML, Relapsed, CML, Refractory
Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments
The main study (CLR_15_03) was terminated prematurely for non-safety reasons due to changes in the clinical treatment landscape and evolving regulatory considerations.
- Trial name
- NCT07517315
- Testing
- K0706
- Where
- 10 sites in United States, France and 5 more
- Sponsor
- Sun Pharma Advanced Research Company Limited
Chronic Myelogenous Leukemia
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.
- Trial name
- NCT02511340
- Testing
- Flumatinib mesylate tablet 600 mg qd
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lymphoma, Small Lymphocytic, Lymphoma
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
- Conditions
- Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
- Trial name
- REAL (NCT04342117)
- Testing
- duvelisib, PI3K inhibitor
- Where
- 11 sites in United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- EPCORE™ NHL-3 (NCT04542824)
- Testing
- Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 15 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Genmab
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory…
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05020678
- Testing
- NKX019
- Where
- 6 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Nkarta, Inc.
Chronic Lymphocytic Leukemia, B-cell Lymphomas
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
- Trial name
- NCT02891590
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang DTRM Biopharma
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00522990
- Testing
- AT9283
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04072458
- Testing
- L-Bcl-2 antisense oligonucleotide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bio-Path Holdings, Inc.
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic…
- Trial name
- NCT02081378
- Testing
- Asciminib (ABL001), Nilotinib, Imatinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
This study will examine the effectiveness of MabThera therapy added to a standard chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02080884
- Where
- 15 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment…
- Trial name
- NCT02085798
- Testing
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
- Where
- 50 sites in Spain
- Volunteers
- 503 people
- Sponsor
- Celgene
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Leukemia, Lymphocytic, Chronic
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals.
- Trial name
- NCT00289549
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- BioCryst Pharmaceuticals
Healthy Volunteers
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in…
- Trial name
- NCT07527221
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eilean Therapeutics AU Pty Ltd